Intratumor Heterogeneity in Evolutionary Models of Tumor Progression

With rare exceptions, human tumors arise from single cells that have accumulated the necessary number and types of heritable alterations. Each such cell leads to dysregulated growth and eventually the formation of a tumor. Despite their monoclonal origin, at the time of diagnosis most tumors show a striking amount of intratumor heterogeneity in all measurable phenotypes; such heterogeneity has implications for diagnosis, treatment efficacy, and the identification of drug targets. An understanding of the extent and evolution of intratumor heterogeneity is therefore of direct clinical importance. In this article, we investigate the evolutionary dynamics of heterogeneity arising during exponential expansion of a tumor cell population, in which heritable alterations confer random fitness changes to cells. We obtain analytical estimates for the extent of heterogeneity and quantify the effects of system parameters on this tumor trait. Our work contributes to a mathematical understanding of intratumor heterogeneity and is also applicable to organisms like bacteria, agricultural pests, and other microbes.

[1]  R. Durrett Probability: Theory and Examples , 1993 .

[2]  S. Resnick Extreme Values, Regular Variation, and Point Processes , 1987 .

[3]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[4]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[5]  R. Durrett,et al.  Evolutionary dynamics of tumor progression with random fitness values. , 2010, Theoretical population biology.

[6]  Martin A. Nowak,et al.  Genetic Progression and the Waiting Time to Cancer , 2007, PLoS Comput. Biol..

[7]  Goldie Jh,et al.  Role of mathematical modeling in protocol formulation in cancer chemotherapy. , 1985 .

[8]  Paul Loya Dirichlet and Fresnel Integrals via Iterated Integration , 2005 .

[9]  N. Komarova,et al.  Stochastic modeling of drug resistance in cancer. , 2006, Journal of theoretical biology.

[10]  Rafael Sanjuán,et al.  The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Dick,et al.  Stem cell concepts renew cancer research. , 2008, Blood.

[12]  Yoh Iwasa,et al.  The Evolution of Two Mutations During Clonal Expansion , 2007, Genetics.

[13]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[14]  M. S. Ridout,et al.  Generating random numbers from a distribution specified by its Laplace transform , 2009, Stat. Comput..

[15]  S. Wolman Cytogenetic heterogeneity: its role in tumor evolution. , 1986, Cancer genetics and cytogenetics.

[16]  Hansjörg Albrecher,et al.  Asymptotic analysis of a measure of variation , 2007 .

[17]  G. Nicolson Generation of phenotypic diversity and progression in metastatic tumor cells , 2004, Cancer and Metastasis Reviews.

[18]  John D Pfeifer,et al.  Tumor Heterogeneity Affects the Precision of Microarray Analysis , 2005, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[19]  Kornelia Polyak,et al.  Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution? , 2007, Cell cycle.

[20]  Carissa A. Sanchez,et al.  Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array‐CGH , 2007, Genes, chromosomes & cancer.

[21]  Richard Durrett,et al.  Evolution of Resistance and Progression to Disease during Clonal Expansion of Cancer , 2009 .

[22]  Lars Egevad,et al.  The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer , 2005, Scandinavian journal of urology and nephrology.

[23]  R. Lenski,et al.  Dynamics of adaptation and diversification: a 10,000-generation experiment with bacterial populations. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Martin T. Ferris,et al.  Beneficial Fitness Effects Are Not Exponential for Two Viruses , 2008, Journal of Molecular Evolution.

[25]  R. Lenski,et al.  The fate of competing beneficial mutations in an asexual population , 2004, Genetica.

[26]  Jason Schweinsberg,et al.  The waiting time for m mutations , 2008, 0802.3485.

[27]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[28]  J. Krug,et al.  Clonal interference in large populations , 2007, Proceedings of the National Academy of Sciences.

[29]  R. Lenski,et al.  Long-Term Experimental Evolution in Escherichia coli. I. Adaptation and Divergence During 2,000 Generations , 1991, The American Naturalist.

[30]  Q. Shao Self-normalized large deviations , 1997 .

[31]  W. Thilly,et al.  A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. , 1989, Mutation research.

[32]  M. Foley,et al.  Quinoline antimalarials: mechanisms of action and resistance. , 1997, International journal for parasitology.

[33]  A. Morley,et al.  Mutation rate of normal and malignant human lymphocytes. , 1987, Cancer research.

[34]  J. Krug,et al.  The Speed of Evolution in Large Asexual Populations , 2009, 0910.0219.

[35]  R Rosen,et al.  "Role of mathematical modeling in protocol formulation in cancer chemotherapy". , 1986, Cancer treatment reports.

[36]  M Imhof,et al.  Fitness effects of advantageous mutations in evolving Escherichia coli populations. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Sevin,et al.  Evidence of tumor heterogeneity in cervical cancers and lymph node metastases as determined by flow cytometry , 1993, Cancer.

[38]  Jozef L. Teugels,et al.  Expectation of the Ratio of the Sum of Squares to the Square of the Sum: Exact and Asymptotic Results , 2002 .

[39]  Rick Durrett,et al.  Traveling waves of selective sweeps , 2009, 0910.5730.

[40]  J H Goldie,et al.  A stochastic model for the origin and treatment of tumors containing drug-resistant cells. , 1986, Bulletin of mathematical biology.

[41]  G. Heppner,et al.  Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA 100. , 1984, Cancer research.

[42]  G. Heppner Tumor heterogeneity. , 1984, Cancer research.

[43]  Lei Si Ni Ke Resnick.S.I. Extreme values. regular variation. and point processes , 2011 .

[44]  S Torquato,et al.  Emergence of a Subpopulation in a Computational Model of Tumor Growth , 2022 .

[45]  S. Bhunya,et al.  Cytogenetic effects of fenvalerate in mammalian in vivo test system. , 1989, Mutation research.

[46]  C. Mallows,et al.  Limit Distributions of Self-normalized Sums , 1973 .

[47]  T. Kunkel DNA Replication Fidelity* , 2004, Journal of Biological Chemistry.

[48]  K. Ito,et al.  Stochastic models for subpopulation emergence in heterogeneous tumors. , 1989, Bulletin of mathematical biology.

[49]  I. Fidler,et al.  Biological diversity in metastatic neoplasms: origins and implications. , 1982, Science.

[50]  I. Fidler,et al.  Tumor heterogeneity and the biology of cancer invasion and metastasis. , 1978, Cancer research.